Evidence map›Paper›PMID 36432709›Full record

ArticlePharmaceutics2022

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis.

Yongsheng Liu, Rezan Güler, Yunqi Liao, Anzhelika Vorobyeva, Olof Widmark, Theodorus J Meuleman, Anna Koijen, Leendert J van den Bos, Robert Naasz, Vitalina Bodenko and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Evaluation of a novelEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Yongsheng LiuDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-5871-5779
Rezan GülerAffibody AB, 171 65 Solna, Sweden.
Yunqi LiaoDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-6038-8295
Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-4778-3909
Olof WidmarkAffibody AB, 171 65 Solna, Sweden.
Theodorus J MeulemanEnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands.
Anna KoijenEnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands.ORCID 0000-0003-2375-334X
Leendert J van den BosEnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands.ORCID 0000-0003-2410-5838
Robert NaaszEnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands.
Vitalina BodenkoResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
Anna OrlovaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0001-6120-2683
Caroline EkbladAffibody AB, 171 65 Solna, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-6421-4142
Uppsala University · SEAffibody (Sweden) · SENational Research Tomsk State University · RU

Funding

Swedish Cancer Society 20 0181 PSwedish Cancer Society 20 0893Swedish Cancer Society 21 1485 PjSwedish Research Council 2019-00994Swedish Research Council VR 2019-00986
6 · The paper itself

Abstract

Targeted molecular radiation therapy is a promising emerging treatment modality in oncology, and peptide synthesis may shorten the time to reach the clinical stage. In this study, we have explored Chemo-Enzymatic Peptide Synthesis, or CEPS, as a new means of producing a therapeutic HER2 targeted Affibody

Indexed as

177LuAffibody moleculealbumin binding domain (ABD)biodistributionDOTAenzymatic ligationpeptide synthesisradionuclide therapyscaffold proteinSKOV-3 xenograft

Identifiers

PMID36432709
PMCPMC9698269
OpenAlexW4309720349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.